

Advanced Control Specialty Formulary®

July 2022 Updates

Removals	Add-Backs
5	0

Removals

Drug Class	Removed Product(s)	Formulary Options
Cancer, BRAF Kinase Inhibitors	TAFINLAR	BRAFTOVI, ZELBORAF
Cancer, MEK Inhibitors	MEKINIST	COTELLIC, MEKTOVI
Cancer, mTOR Inhibitors*	AFINITOR DISPERZ**	everolimus
Cardiovascular, Antilipemics, Microsomal Triglyceride Transfer Protein Inhibitors	JUXTAPID	PRALUENT
Cushing Syndrome	KORLYM	Consult doctor
Cystic Fibrosis, Inhaled Antibiotics*	CAYSTON	tobramycin inhalation solution, BETHKIS

Add-Backs

Drug Class	Product(s) Added Back
Endometriosis*, Uterine Fibroids	LUPRON DEPOT 3.75 mg and 11.25 mg (non-preferred)

Indication Based Strategy Updates

Indication	Product(s) Removed
Ankylosing Spondylitis	XELJANZ, XELJANZ XR

Indication	Product(s) Added
Ulcerative Colitis	RINVOQ

* Class has existing formulary exclusions

** Multi-source Brand Product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

Removals and Add-Backs as of April 29, 2022. Information subject to change.

©2022 CVS Caremark. All rights reserved. 106-54612C 043021